Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Abattis Bioceuticals Corp ATTBF

Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The company is also engaged in growing, extraction, testing, propagation and online distribution.


GREY:ATTBF - Post by User

Bullboard Posts
Post by PEAACONon Feb 14, 2018 1:35am
225 Views
Post# 27555500

Put legitimacy of GTT deal to rest???

Put legitimacy of GTT deal to rest???

Abattis has been tight-lipped regarding the GT Therapeudics acquisition - This has caused uneasiness amongst some of us because it was probably the biggest deal Abattis has ever done - for sure the largest I have ever seen (by $ value that is). With the GT Therapeudics' website down and practically zero information online etc... (I know I have searched hours looking for vape pens!) Eventually there are rumblings about GTT being nothing more than a shell company - This old Winston Resources News Release will provide insight on the level of DD Winston was completing on GTT - My DD has provided myself with more than enough confidence that GTT was a real company and that the acquisition our Team accomplished was admirable. Highlights from this OLD NR below, 

"Mr. Jang brings more than 25 years of experience in the mining industry and has extensive knowledge of Sarbanes-Oxley, internal controls, mergers and acquisitions, tax planning, and regulatory compliance matters."

"Mr. Jang has worked with Lundin Mining Corp., Augusta Resources Corp., Hudbay Minerals Inc. and Pan American Silver Corp. in various roles ranging from corporate controller to vice-president. He is a graduate of the British Columbia Institute of Technology's financial management program and holds a CPA, CMA designation."

2017-03-07 10:20 ET - News Release

Mr. Shawn Bromley reports

WINSTON RESOURCES INC. APPOINTS GORDON JANG AS CHAIRMAN OF ADVISORY BOARD

Winston Resources Inc., in conjunction with its proposed acquisition of Green Tree Therapeutics, has appointed Gordon Jang as chairman of the company's advisory board. The advisory board will enhance the company's ability to bring in tactical growth partnerships through strategic investments, which are an important part of the company's approach to capture sales and the newest developing technologies in the cannabinoid sector.

Mr. Jang brings more than 25 years of experience in the mining industry and has extensive knowledge of Sarbanes-Oxley, internal controls, mergers and acquisitions, tax planning, and regulatory compliance matters.

Mr. Jang has worked with Lundin Mining Corp., Augusta Resources Corp., Hudbay Minerals Inc. and Pan American Silver Corp. in various roles ranging from corporate controller to vice-president. He is a graduate of the British Columbia Institute of Technology's financial management program and holds a CPA, CMA designation.

Mr. Jang brings invaluable experience, expertise and insight, and the company looks forward to developing numerous growth strategies. Mr. Jang will be granted options at a later date, subject to approval by the Canadian Securities Exchange.

Update on proposed transaction

On Feb. 24, 2017, Winston signed a letter of intent with GT Therapeutics Corp., doing business as Green Tree Therapeutics, an arm's-length private British Columbia company, pursuant to which the company will complete a reverse takeover and acquire from Green Tree Therapeutics' shareholders 100 per cent of the shares of Green Tree Therapeutics, causing Green Tree Therapeutics to become a wholly owned subsidiary of Winston. On completion of the transaction, the business of Green Tree Therapeutics will become the business of Winston, and the company will abandon the Pigeon River property.

The company continues to work through due diligence and negotiation of the definitive agreement. The transaction remains subject to certain closing conditions, including completion of due diligence, the negotiation and signing of a definitive agreement, and obtaining all necessary approvals, including approval of the respective boards, the approval of the Canadian Securities Exchange, and if applicable, shareholders of the company. There can be no guarantees that the transaction will be completed as proposed or at all.

Bullboard Posts